These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 17461719)

  • 1. Lack of effect of gastric acid-reducing agents on the pharmacokinetics of lopinavir/ritonavir in HIV-infected patients.
    Chiu YL; Klein CE; Woodward WC; King KR; Naylor C; Awni W; Brun S
    AIDS Patient Care STDS; 2007 Apr; 21(4):247-51. PubMed ID: 17461719
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The effect of acid reduction with a proton pump inhibitor on the pharmacokinetics of lopinavir or ritonavir in HIV-infected patients on lopinavir/ritonavir-based therapy.
    Overton ET; Tschampa JM; Klebert M; Royal M; Rodriguez M; Spitz T; Kim G; Mondy KE; Acosta EP
    J Clin Pharmacol; 2010 Sep; 50(9):1050-5. PubMed ID: 20147613
    [No Abstract]   [Full Text] [Related]  

  • 3. Steady-state pharmacokinetics of a double-boosting regimen of saquinavir soft gel plus lopinavir plus minidose ritonavir in human immunodeficiency virus-infected adults.
    Ribera E; Lopez RM; Diaz M; Pou L; Ruiz L; Falcó V; Crespo M; Azuaje C; Ruiz I; Ocaña I; Clotet B; Pahissa A
    Antimicrob Agents Chemother; 2004 Nov; 48(11):4256-62. PubMed ID: 15504850
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Abacavir plasma pharmacokinetics in the absence and presence of atazanavir/ritonavir or lopinavir/ritonavir and vice versa in HIV-infected patients.
    Waters LJ; Moyle G; Bonora S; D'Avolio A; Else L; Mandalia S; Pozniak A; Nelson M; Gazzard B; Back D; Boffito M
    Antivir Ther; 2007; 12(5):825-30. PubMed ID: 17713166
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Amprenavir and lopinavir pharmacokinetics following coadministration of amprenavir or fosamprenavir with lopinavir/ritonavir, with or without efavirenz.
    Pham PA; Hendrix CW; Barditch-Crovo P; Parsons T; Khan W; Parish M; Radebaugh C; Carson KA; Pakes GE; Qaqish R; Flexner C
    Antivir Ther; 2007; 12(6):963-9. PubMed ID: 17926651
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of acid-reducing agents on the pharmacokinetics of lopinavir/ritonavir and ritonavir-boosted atazanavir.
    Klein CE; Chiu YL; Cai Y; Beck K; King KR; Causemaker SJ; Doan T; Esslinger HU; Podsadecki TJ; Hanna GJ
    J Clin Pharmacol; 2008 May; 48(5):553-62. PubMed ID: 18440920
    [TBL] [Abstract][Full Text] [Related]  

  • 7. "White coat compliance" limits the reliability of therapeutic drug monitoring in HIV-1-infected patients.
    Podsadecki TJ; Vrijens BC; Tousset EP; Rode RA; Hanna GJ
    HIV Clin Trials; 2008; 9(4):238-46. PubMed ID: 18753118
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetics of a once-daily regimen of lopinavir/ritonavir in HIV-1-infected children.
    van der Lee M; Verweel G; de Groot R; Burger D
    Antivir Ther; 2006; 11(4):439-45. PubMed ID: 16856617
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lopinavir/Ritonavir pharmacokinetic profile: impact of sex and other covariates following a change from twice-daily to once-daily therapy.
    Ofotokun I; Chuck SK; Binongo JN; Palau M; Lennox JL; Acosta EP
    J Clin Pharmacol; 2007 Aug; 47(8):970-7. PubMed ID: 17615254
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Once-daily atazanavir/ritonavir versus twice-daily lopinavir/ritonavir, each in combination with tenofovir and emtricitabine, for management of antiretroviral-naive HIV-1-infected patients: 48 week efficacy and safety results of the CASTLE study.
    Molina JM; Andrade-Villanueva J; Echevarria J; Chetchotisakd P; Corral J; David N; Moyle G; Mancini M; Percival L; Yang R; Thiry A; McGrath D;
    Lancet; 2008 Aug; 372(9639):646-55. PubMed ID: 18722869
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetics and 48 week efficacy of low-dose lopinavir/ritonavir in HIV-infected children.
    Puthanakit T; van der Lugt J; Bunupuradah T; Ananworanich J; Gorowara M; Phasomsap C; Jupimai T; Boonrak P; Pancharoen C; Burger D; Ruxrungtham K
    J Antimicrob Chemother; 2009 Nov; 64(5):1080-6. PubMed ID: 19729375
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lopinavir.
    Hurst M; Faulds D
    Drugs; 2000 Dec; 60(6):1371-9; discussion 1380-1. PubMed ID: 11152017
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Exploratory study comparing the metabolic toxicities of a lopinavir/ritonavir plus saquinavir dual protease inhibitor regimen versus a lopinavir/ritonavir plus zidovudine/lamivudine nucleoside regimen.
    Cameron DW; Becker S; King MS; da Silva B; Klein C; Tokimoto D; Foit C; Calhoun D; Bernstein B; Hanna GJ
    J Antimicrob Chemother; 2007 May; 59(5):957-63. PubMed ID: 17350990
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lopinavir/ritonavir pharmacokinetics in HIV and hepatitis C virus co-infected patients without liver function impairment: influence of liver fibrosis.
    Moltó J; Valle M; Blanco A; Negredo E; DelaVarga M; Miranda C; Miranda J; Domingo P; Vilaró J; Tural C; Costa J; Barbanoj MJ; Clotet B
    Clin Pharmacokinet; 2007; 46(1):85-92. PubMed ID: 17201460
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Increased dose of lopinavir/ritonavir compensates for efavirenz-induced drug-drug interaction in HIV-1-infected children.
    Bergshoeff AS; Fraaij PL; Ndagijimana J; Verweel G; Hartwig NG; Niehues T; De Groot R; Burger DM
    J Acquir Immune Defic Syndr; 2005 May; 39(1):63-8. PubMed ID: 15851915
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Simultaneous population pharmacokinetic model for lopinavir and ritonavir in HIV-infected adults.
    Moltó J; Barbanoj MJ; Miranda C; Blanco A; Santos JR; Negredo E; Costa J; Domingo P; Clotet B; Valle M
    Clin Pharmacokinet; 2008; 47(10):681-92. PubMed ID: 18783298
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lopinavir/ritonavir in the treatment of human immunodeficiency virus infection.
    Kaplan SS; Hicks CB
    Expert Opin Pharmacother; 2005 Aug; 6(9):1573-85. PubMed ID: 16086645
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lopinavir/ritonavir: appraisal of its use in HIV therapy.
    von Hentig N
    Drugs Today (Barc); 2007 Apr; 43(4):221-47. PubMed ID: 17460785
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mutual pharmacokinetic interactions between bosentan and lopinavir/ritonavir in healthy participants.
    Dingemanse J; van Giersbergen PL; Patat A; Nilsson PN
    Antivir Ther; 2010; 15(2):157-63. PubMed ID: 20386070
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Absence of circadian variation in the pharmacokinetics of lopinavir/ritonavir given as a once daily dosing regimen in HIV-1-infected patients.
    van Heeswijk RP; Bourbeau M; Seguin I; Giguere P; Garber GE; Cameron DW
    Br J Clin Pharmacol; 2005 Apr; 59(4):398-404. PubMed ID: 15801934
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.